Clinical Trial Update: Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating valganciclovir to prevent cytomegalovirus infection after donor stem cell transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Valganciclovir (Valganciclovir)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Infection | Phase 3 | Status: COMPLETED